Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Equity Average (2018 - 2025)

Historic Equity Average for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $269.4 million.

  • Neurogene's Equity Average rose 8424.88% to $269.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $269.4 million, marking a year-over-year increase of 8424.88%. This contributed to the annual value of $248.2 million for FY2024, which is N/A changed from last year.
  • Neurogene's Equity Average amounted to $269.4 million in Q3 2025, which was up 8424.88% from $282.5 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Equity Average ranged from a high of $301.1 million in Q1 2025 and a low of $77.4 million during Q3 2023
  • Over the past 3 years, Neurogene's median Equity Average value was $162.9 million (recorded in 2024), while the average stood at $181.3 million.
  • The largest annual percentage gain for Neurogene's Equity Average in the last 5 years was 10243.89% (2024), contrasted with its biggest fall of 2666.13% (2024).
  • Neurogene's Equity Average (Quarter) stood at $130.6 million in 2023, then skyrocketed by 71.4% to $223.9 million in 2024, then increased by 20.32% to $269.4 million in 2025.
  • Its Equity Average stands at $269.4 million for Q3 2025, versus $282.5 million for Q2 2025 and $301.1 million for Q1 2025.